Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Jaffer A. Ajani, Giuseppe Aprile et al.|The Lancet|2023Cited by 701
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A. Shah, Rui‐Hua Xu, Kohei Shitara et al.|Nature Medicine|2023Cited by 541
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaUğur Şahin, S. Al-Batran, Ö. Türeci et al.|Annals of Oncology|2021Cited by 357
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO studyÖ. Türeci, Martin Schüler, Uğur Şahin et al.|Annals of Oncology|2019Cited by 244